Contrast-enhanced ultrasound may avert prostate biopsies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies.

A protocol involving contrast-enhanced ultrasound could better target tumors and reduce the number of unnecessary prostate biopsies, according to international researchers. In studies from China and Austria, investigators imaged patients with contrast ultrasound and used the information to target biopsies. They found generally that contrast ultrasound provided more precise locational information than is available with unenhanced grayscale ultrasound. Biopsies based on the contrast scans resulted in a sensitivity of 85.2%, according to the group from the Medical University of Innsbruck (European Congress of Radiology 2009 abstract C-390).

A group at Shanghai’s Jio Tong University used microflow imaging and found a sensitivity of 80% and an accuracy of 83% for this contrast strategy. However, limitations included cost and training (abstract C-391).

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content